Shares of the biotech Sage Therapeutics were up nearly 40% on Monday after the company’s partner Biogen threw it a lifeline late Friday. Little has gone right for Sage in recent years ...

SAN FRANCISCO (Reuters) - Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company's CEO ...

The proposed merger of the two Cambridge drugmakers is off, but Sage says it's open to "strategic alternatives" — including a sale. Sage Therapeutics Inc. is looking for a deal — but it’s ...

Jan 10 (Reuters) - Drugmaker Biogen (BIIB.O), opens new tab will buy all outstanding shares of Sage Therapeutics (SAGE.O), opens new tab that it does not already own for $7.22 apiece, a filing ...

BMO Capital says Biogen (BIIB) is looking for an early potential deal by offering to buy Sage Therapeutics (SAGE) for $7.22 per share. Such an offer reflects Biogen’s interest in reducing its ...

Biogen has offered to purchase Sage’s outstanding shares for $7.22 each, according to a securities filing from Friday. The proposal values Sage at around $442 million. A yearslong partner of ...

Biogen on Tuesday pledged a return to earnings growth this year after three years of slippage, but that wasn’t enough to keep investors from sending the share price down 4.9% in morning trading ...

After a 2024 marred by a series of trial failures, Sage Therapeutics Inc. has received an acquisition offer from longtime partner Biogen Inc. on the eve of the biggest biotech event of the year.

The stock’s performance has been below most large drugmakers’ performance. Biogen's revenues declined 3% in the first nine months of 2024. Sales of Biogen’s key multiple sclerosis (“MS ...